Information

Coronavirus (COVID-19) vaccine - Comirnaty® 10 micrograms/dose (mRNA, Pfizer/BioNTech): national protocol v1.0

Protocol for the supply and administration of Comirnaty® 10 micrograms/dose (COVID-19 mRNAVaccine, Pfizer/BioNTech) national protocol v1.0.


Annex C: Clinical Supervision sheet

Comirnaty® 10 micrograms/dose (COVID-19 mRNA Vaccine, Pfizer/BioNTech) Protocol

Valid from:

Expiry:

This sheet must record the name of the clinical supervisor taking responsibility and all of the people working under different activity stages of the protocol.

Activity stages of the vaccination pathway under this protocol:

Stage 1

a. Assessment of the individual presenting for vaccination

b. Provide information and obtain informed consent

c. Provide advice to the individual

d. Capacity for under 16s should be assessed in line with current practices for existing childhood vaccination programmes

Registered Healthcare Professionals Only

Stage 2

  • Vaccine Preparation

Registered Healthcare Professionals, non-registered professionals or non-registered Armed Forces staff

Stage 3

  • Vaccine Administration

Registered Healthcare Professionals, non-registered professionals or non-registered Armed Forces staff

Stage 4

  • Record Keeping

Registered Healthcare Professionals, non-registered professionals or non-registered Armed Forces staff

The clinical supervisor has ultimate responsibility for safe care being provided under the terms of the protocol. Persons working under the protocol may be supported by additional registered healthcare professionals, but the clinical supervisor retains responsibility.

Before signing this Protocol, check that the document has had the necessary authorisations. Without these, this Protocol is not lawfully valid.

Clinical Supervisor

Name

Designation

Signature

Date

Practitioner(s) and Activity Stages

Name

Activity Stage(s)

Signature

Date

Note to Clinical Supervisor

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of clinical supervision arrangements for those working under this Protocol.

Annex Version History

Version Date Summary of changes
1.0 14.01.22 Version 1.0 new Annex A
1.0 25/01/22
The following sections have been updated: Frequency section updated to include course consisting of two separate doses of 0.2ml each, a minimum of 21 days apart.

Contact

Email: CEU@gov.scot

Back to top